{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:19:32Z","timestamp":1792790372635,"version":"4.5.0"},"posted":{"date-parts":[[2026,10,2]]},"group-title":"Cancer Biology","reference-count":52,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"award":["CA220769"],"award-info":[{"award-number":["CA220769"]}],"id":[{"id":"https:\/\/ror.org\/0447fe631","id-type":"ROR","asserted-by":"publisher"}]},{"award":["CA235681"],"award-info":[{"award-number":["CA235681"]}],"id":[{"id":"https:\/\/ror.org\/01cwqze88","id-type":"ROR","asserted-by":"publisher"}]},{"award":["CA006973"],"award-info":[{"award-number":["CA006973"]}],"id":[{"id":"https:\/\/ror.org\/01cwqze88","id-type":"ROR","asserted-by":"publisher"}]},{"award":["Young Investigator Award"],"award-info":[{"award-number":["Young Investigator Award"]}],"id":[{"id":"https:\/\/ror.org\/04p3pep55","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Commonwealth Foundation","id":[{"id":"https:\/\/ror.org\/05rhej692","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Johns Hopkins Greenberg Bladder Cancer Institute"},{"name":"The John and Camilla Duffy Urologic Oncology Research Fund"},{"name":"Japanese Society for the Promotion of Science","award":["Overseas Research Fellowship"],"award-info":[{"award-number":["Overseas Research Fellowship"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>Patients with majority variant subtype histology including sarcomatoid urothelial carcinoma (SUC) have poor outcomes and limited treatment options, and there are few preclinical resources to investigate rare histologic subtypes. We developed three novel variant subtype histology bladder cancer (BC) cell lines by finding that basal BC tumor cells derived from mice treated with N-butyl-N-(4-hydroxybutyl)-nitrosamine (BBN) were initially not competent to grow in immune competent mice, but then acquired tumorigenicity following passaging (\u201crecycling\u201d) in mice lacking mature B and T cells. Three genitourinary oncology pathologists identified BBN966 as SUC, BBN964 as a hybrid between SUC and squamous, and BBN975 as squamous, and each had unique growth characteristics. Using a publicly available dataset and our spatial transcriptomics analysis of a cohort of human tumors with mixed SUC and UC as comparators, we found that consistent with human SUC, BBN966 lack expression of basal and luminal genes. Consistent with human SUC and spatial transcriptomics analysis of canine SUC, BBN966 had the highest epithelial to mesenchymal transition (EMT) upregulation, and all three recycled tumor cells had increased EMT pathway expression in recycled tumor cells. Moreover, increased expression of genes upregulated in all three recycled tumor cells associated with worse overall survival in patients with muscle invasive UC. Similar to human SUC, BBN966 tumors had higher proportion of M2 macrophage gene expression. Finally, we found in the largest cohort of PD-L1 IHC to date that 20 of 38 (52.6%) human SUC had CPS \u2265 50, which was driven mostly by tumor proportion score. Consistent with this, we found anti-PD1 immune checkpoint inhibitor (ICI) significantly inhibited BBN966 tumor growth, while the hybrid BBN964 tumors had mixed response to ICI. Thus, the murine BBN966 tumors exhibited similarities to human SUC, and can be used to examine novel therapies for translation into future SUC clinical studies.<\/jats:p>","DOI":"10.64898\/2026.09.30.755727","type":"posted-content","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:25:24Z","timestamp":1790929524000},"source":"Crossref","is-referenced-by-count":0,"title":["Epithelial to mesenchymal transition and M2 macrophages drive aggressiveness in murine and human sarcomatoid urothelial carcinoma"],"prefix":"10.64898","author":[{"given":"Yujiro","family":"Hayashi","sequence":"first","affiliation":[{"name":"Greenberg Bladder Cancer Institute, Johns Hopkins University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Elias","sequence":"additional","affiliation":[{"name":"Greenberg Bladder Cancer Institute, Johns Hopkins University"},{"name":"Department of Oncology, Johns Hopkins University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Douglass","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinaru","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Greenberg Bladder Cancer Institute, Johns Hopkins University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Schuler","sequence":"additional","affiliation":[{"name":"Greenberg Bladder Cancer Institute, Johns Hopkins University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxiao","family":"Feng","sequence":"additional","affiliation":[{"name":"Greenberg Bladder Cancer Institute, Johns Hopkins University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekatherina Y.","family":"Batourina","sequence":"additional","affiliation":[{"name":"Department of Pathology, Columbia University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne E.","family":"Geller","sequence":"additional","affiliation":[{"name":"Department of Urology, Johns Hopkins University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woonyoung","family":"Choi","sequence":"additional","affiliation":[{"name":"Greenberg Bladder Cancer Institute, Johns Hopkins University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Colocho","sequence":"additional","affiliation":[{"name":"Greenberg Bladder Cancer Institute, Johns Hopkins University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"Arbuiso","sequence":"additional","affiliation":[{"name":"Greenberg Bladder Cancer Institute, Johns Hopkins University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Jin","sequence":"additional","affiliation":[{"name":"Greenberg Bladder Cancer Institute, Johns Hopkins University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam K.","family":"Aragaki","sequence":"additional","affiliation":[{"name":"Greenberg Bladder Cancer Institute, Johns Hopkins University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Ruland","sequence":"additional","affiliation":[{"name":"Greenberg Bladder Cancer Institute, Johns Hopkins University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Rapiey","sequence":"additional","affiliation":[{"name":"Greenberg Bladder Cancer Institute, Johns Hopkins University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Hoffman-Censits","sequence":"additional","affiliation":[{"name":"Greenberg Bladder Cancer Institute, Johns Hopkins University"},{"name":"Department of Oncology, Johns Hopkins University"},{"name":"Department of Urology, Johns Hopkins University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Kates","sequence":"additional","affiliation":[{"name":"Greenberg Bladder Cancer Institute, Johns Hopkins University"},{"name":"Department of Urology, Johns Hopkins University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil H.","family":"Patel","sequence":"additional","affiliation":[{"name":"Greenberg Bladder Cancer Institute, Johns Hopkins University"},{"name":"Department of Urology, Johns Hopkins University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirmish","family":"Singla","sequence":"additional","affiliation":[{"name":"Greenberg Bladder Cancer Institute, Johns Hopkins University"},{"name":"Department of Urology, Johns Hopkins University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armine","family":"Smith","sequence":"additional","affiliation":[{"name":"Greenberg Bladder Cancer Institute, Johns Hopkins University"},{"name":"Department of Urology, Johns Hopkins University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Russell","sequence":"additional","affiliation":[{"name":"Greenberg Bladder Cancer Institute, Johns Hopkins University"},{"name":"Department of Oncology, Johns Hopkins University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huili","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pathology, Johns Hopkins University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua I.","family":"Warrick","sequence":"additional","affiliation":[{"name":"Department of Pathology, Yale University."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezra","family":"Baraban","sequence":"additional","affiliation":[{"name":"Department of Pathology, Johns Hopkins University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Allenspach","sequence":"additional","affiliation":[{"name":"College of Veterinary Medicine, University of Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4026-4073","authenticated-orcid":false,"given":"Cathy L.","family":"Mendelsohn","sequence":"additional","affiliation":[{"name":"Department of Pathology, Columbia University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Matoso","sequence":"additional","affiliation":[{"name":"Department of Pathology, Johns Hopkins University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah M.","family":"Hahn","sequence":"additional","affiliation":[{"name":"Greenberg Bladder Cancer Institute, Johns Hopkins University"},{"name":"Department of Oncology, Johns Hopkins University"},{"name":"Department of Urology, Johns Hopkins University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"McConkey","sequence":"additional","affiliation":[{"name":"Greenberg Bladder Cancer Institute, Johns Hopkins University"},{"name":"Department of Urology, Johns Hopkins University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Burles A.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Greenberg Bladder Cancer Institute, Johns Hopkins University"},{"name":"Department of Oncology, Johns Hopkins University"},{"name":"Department of Urology, Johns Hopkins University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2026100608352260000_2026.09.30.755727v1.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2025.04.008"},{"key":"2026100608352260000_2026.09.30.755727v1.2","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.clgc.2023.05.019","article-title":"Clinicopathologic and Survival After Cystectomy Outcomes in Squamous Cell Carcinoma of the Bladder","volume":"21","year":"2023","journal-title":"Clin. Genitourin. Cancer"},{"key":"2026100608352260000_2026.09.30.755727v1.3","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3233\/BLC-240008","article-title":"Neoadjuvant Cisplatin, Gemcitabine, and Docetaxel in Sarcomatoid Bladder Cancer: Clinical Activity and Whole Transcriptome Analysis","volume":"10","year":"2024","journal-title":"Bladder Cancer"},{"key":"2026100608352260000_2026.09.30.755727v1.4","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000000761"},{"key":"2026100608352260000_2026.09.30.755727v1.5","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/bju.15428","article-title":"Pathological and oncological outcomes in patients with sarcomatoid differentiation undergoing cystectomy","volume":"129","year":"2022","journal-title":"BJU Int"},{"key":"2026100608352260000_2026.09.30.755727v1.6","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-016-1962-8"},{"key":"2026100608352260000_2026.09.30.755727v1.7","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer","volume":"391","year":"2024","journal-title":"N. Engl. J. Med"},{"key":"2026100608352260000_2026.09.30.755727v1.8","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa2601486","article-title":"Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer","volume":"395","year":"2026","journal-title":"N. Engl. J. Med"},{"key":"2026100608352260000_2026.09.30.755727v1.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511674"},{"key":"2026100608352260000_2026.09.30.755727v1.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312117"},{"key":"2026100608352260000_2026.09.30.755727v1.11","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.eururo.2025.09.003","article-title":"Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE Study","volume":"90","year":"2026","journal-title":"Eur. Urol"},{"key":"2026100608352260000_2026.09.30.755727v1.12","doi-asserted-by":"crossref","unstructured":"Lang, H. et al. Integrated molecular and pharmacological characterization of patient-derived xenografts from bladder and ureteral cancers identifies new potential therapies. Front. Oncol. 12, 930731 (2022).","DOI":"10.3389\/fonc.2022.930731"},{"key":"2026100608352260000_2026.09.30.755727v1.13","doi-asserted-by":"crossref","unstructured":"Garioni, M. et al. Patient-derived organoids identify tailored therapeutic options and determinants of plasticity in sarcomatoid urothelial bladder cancer. NPJ Precis . Oncol. 7, (2023).","DOI":"10.1038\/s41698-023-00466-w"},{"key":"2026100608352260000_2026.09.30.755727v1.14","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/path.6060","article-title":"Progression-associated molecular changes in basal\/squamous and sarcomatoid bladder carcinogenesis","volume":"259","year":"2023","journal-title":"J. Pathol"},{"key":"2026100608352260000_2026.09.30.755727v1.15","doi-asserted-by":"crossref","first-page":"e70021","DOI":"10.1002\/2056-4538.70021","article-title":"Sarcomatoid areas of urothelial carcinoma are enriched for CD163-positive antigen-presenting cells","volume":"11","year":"2025","journal-title":"J. Pathol. Clin. Res"},{"key":"2026100608352260000_2026.09.30.755727v1.16","doi-asserted-by":"crossref","unstructured":"Liu, N. et al. standR: spatial transcriptomic analysis for GeoMx DSP data. Nucleic Acids Res. 52, (2024).","DOI":"10.1093\/nar\/gkad1026"},{"key":"2026100608352260000_2026.09.30.755727v1.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2019.04.048"},{"key":"2026100608352260000_2026.09.30.755727v1.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.09.006"},{"key":"2026100608352260000_2026.09.30.755727v1.19","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3593"},{"key":"2026100608352260000_2026.09.30.755727v1.20","doi-asserted-by":"crossref","unstructured":"Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417 (2015).","DOI":"10.1016\/j.cels.2015.12.004"},{"key":"2026100608352260000_2026.09.30.755727v1.21","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-7493-1_12"},{"key":"2026100608352260000_2026.09.30.755727v1.22","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2018-3954"},{"key":"2026100608352260000_2026.09.30.755727v1.23","doi-asserted-by":"publisher","DOI":"10.1038\/35074122"},{"key":"2026100608352260000_2026.09.30.755727v1.24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0005623"},{"key":"2026100608352260000_2026.09.30.755727v1.25","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.408104"},{"key":"2026100608352260000_2026.09.30.755727v1.26","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-2050"},{"key":"2026100608352260000_2026.09.30.755727v1.27","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1001\/jamaoncol.2022.3707","article-title":"Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer: Systematic Review and Meta-analysis of 17 Phase 3 Randomized Clinical Trials","volume":"8","year":"2022","journal-title":"JAMA Oncol"},{"key":"2026100608352260000_2026.09.30.755727v1.28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774"},{"key":"2026100608352260000_2026.09.30.755727v1.29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034442"},{"key":"2026100608352260000_2026.09.30.755727v1.30","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.euo.2021.07.003","article-title":"Gender-specific Stratification of Survival Following Immune Checkpoint Inhibitor Therapy Based on Intratumoral Expression of a B cell Gene Signature. Eur","volume":"5","year":"2022","journal-title":"Urol. Oncol"},{"key":"2026100608352260000_2026.09.30.755727v1.31","doi-asserted-by":"crossref","unstructured":"Li, H. et al. Clinicopathologic and Prognostic Features of Sarcomatoid Urothelial Carcinoma: A Retrospective Study of 136 Patients With Emphasis on Early-Stage (pT1) Disease. Am. J. Surg. Pathol. 50, (2026).","DOI":"10.1097\/PAS.0000000000002468"},{"key":"2026100608352260000_2026.09.30.755727v1.32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613683"},{"key":"2026100608352260000_2026.09.30.755727v1.33","doi-asserted-by":"crossref","unstructured":"Koehne, E. L. et al. Adjuvant Chemotherapy and Survival After Radical Cystectomy in Histologic Subtype Bladder Cancer. Clin. Genitourin. Cancer 22, (2024).","DOI":"10.1016\/j.clgc.2024.102100"},{"key":"2026100608352260000_2026.09.30.755727v1.34","doi-asserted-by":"crossref","unstructured":"Zhang, F. et al. TGF-\u03b2 induces M2-like macrophage polarization via SNAIL-mediated suppression of a pro-inflammatory phenotype. Oncotarget 7, 52294 (2016).","DOI":"10.18632\/oncotarget.10561"},{"issue":"1","key":"2026100608352260000_2026.09.30.755727v1.35","first-page":"6","article-title":"Conditional ablation of TGF-\u03b2 signaling inhibits tumor progression and invasion in an induced mouse bladder cancer model","volume":"6","year":"2016","journal-title":"Scientific Reports"},{"key":"2026100608352260000_2026.09.30.755727v1.36","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-1300"},{"key":"2026100608352260000_2026.09.30.755727v1.37","doi-asserted-by":"crossref","unstructured":"Rakina, M. , Larionova, I. & Kzhyshkowska, J . Macrophage diversity in human cancers: New insight provided by single-cell resolution and spatial context. Heliyon 10, (2024).","DOI":"10.1016\/j.heliyon.2024.e28332"},{"key":"2026100608352260000_2026.09.30.755727v1.38","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-25-1774"},{"key":"2026100608352260000_2026.09.30.755727v1.39","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.21037\/tau-24-7","article-title":"Towards circulating tumor DNA-guided treatment of muscle-invasive bladder cancer","volume":"13","year":"2024","journal-title":"Transl. Androl. Urol"},{"key":"2026100608352260000_2026.09.30.755727v1.40","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","article-title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","volume":"595","year":"2021","journal-title":"Nature"},{"key":"2026100608352260000_2026.09.30.755727v1.41","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.eururo.2023.06.007","article-title":"Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma","volume":"85","year":"2024","journal-title":"Eur. Urol"},{"key":"2026100608352260000_2026.09.30.755727v1.42","doi-asserted-by":"publisher","DOI":"10.1016\/J.EURURO.2025.11.011"},{"key":"2026100608352260000_2026.09.30.755727v1.43","doi-asserted-by":"crossref","unstructured":"Elias, R. et al. Intratumoral Expression of a Composite B Cell \/ CD8 T Cell Biomarker Stratifies Overall Survival by Circulating Tumor DNA Status and Benefit From Adjuvant Immunotherapy in High-Risk Muscle-Invasive Urothelial Carcinoma. J. Urol. 215, (2026).","DOI":"10.1097\/JU.0000000000004828"},{"key":"2026100608352260000_2026.09.30.755727v1.44","doi-asserted-by":"publisher","DOI":"10.3390\/cells8101118"},{"key":"2026100608352260000_2026.09.30.755727v1.45","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1918167117"},{"key":"2026100608352260000_2026.09.30.755727v1.46","doi-asserted-by":"crossref","first-page":", e85902","DOI":"10.1172\/jci.insight.85902","article-title":"Claudin-low bladder tumors are immune infiltrated and actively immune suppressed","volume":"1","year":"2016","journal-title":"JCI Insight"},{"key":"2026100608352260000_2026.09.30.755727v1.47","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-10-0570"},{"key":"2026100608352260000_2026.09.30.755727v1.48","doi-asserted-by":"crossref","unstructured":"Chen, L. et al. Metastasis is regulated via microRNA-200\/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat. Commun. 5, (2014).","DOI":"10.1038\/ncomms6241"},{"key":"2026100608352260000_2026.09.30.755727v1.49","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20160801"},{"issue":"703","key":"2026100608352260000_2026.09.30.755727v1.50","first-page":"e1","article-title":"Assessment of tumoral PD-L1 expression and intratumoral CD8+ T cells in urothelial carcinoma","volume":"85","year":"2015","journal-title":"Urology"},{"key":"2026100608352260000_2026.09.30.755727v1.51","doi-asserted-by":"crossref","unstructured":"Davis, A. A. & Patel, V. G . The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. J. Immunother. Cancer 7, 278 (2019).","DOI":"10.1186\/s40425-019-0768-9"},{"key":"2026100608352260000_2026.09.30.755727v1.52","doi-asserted-by":"publisher","DOI":"10.1038\/nature25501"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.09.30.755727","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:35:35Z","timestamp":1791300935000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.64898\/2026.09.30.755727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":52,"URL":"https:\/\/doi.org\/10.64898\/2026.09.30.755727","relation":{},"subject":[],"published":{"date-parts":[[2026,10,2]]},"subtype":"preprint"}}